spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bupropion 

 HSMN NewsFeed - 12 May 2021
Centers for Medicare and Medicaid Services (CMS) Issues Permanent J-Code for Tolmar's FENSOLVI(R) Effective July 1, 2021
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 4 May 2020
FDA Approves FENSOLVI(R) (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Sep 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Aug 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba(TM) in Germany, France and Austria
Biopharmaceuticals Distribution
 HSMN NewsFeed - 30 Jun 2017
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba(R) (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries
Biopharmaceuticals Distribution
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Biopharmaceuticals Acquisitions Product Launch
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 15 Mar 2016
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Jan 2016
IntelGenx Strengthens Senior Management Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 9 Nov 2015
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 20 Aug 2015
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Aug 2015
Metacrine Raises $36 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 20 Aug 2013
Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 4 Apr 2011
Orexigen(R) Therapeutics Presents Additional Contrave(R) Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
Biopharmaceuticals
 HSMN NewsFeed - 17 Feb 2011
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2011
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2010
Orexigen(R) Therapeutics' Investigational Drug Contrave(R) Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2010
Orexigen(R) Therapeutics Announces FDA Acceptance of Contrave(R) New Drug Application for the Treatment of Obesity
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 May 2010
Mylan Receives Approval for Generic Version of Zyban(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 22 Jan 2010
Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial
Biopharmaceuticals Generics
 HSMN NewsFeed - 6 May 2009
GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
Biopharmaceuticals Asquisitions
 HSMN NewsFeed - 6 May 2009
Biovail Announces Acquisition of U.S. Rights to Wellbutrin XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2009
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2008
Biovail Enters into Commercial Alliance for Aplenzin
Biopharmaceuticals Distribution
 HSMN NewsFeed - 30 May 2008
Teva Announces Launch of Generic Wellbutrin XL(R) Tablets, 150 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 7 May 2008
Orexigen(R) Therapeutics Announces Completion of Patient Enrollment in Phase III Clinical Program for Contrave(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2008
Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 11 Dec 2007
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2007
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2007
Orexigen(TM) Announces Settlement Agreement with Eisai
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Jul 2007
OREXIGEN(TM) Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of EMPATIC(TM) to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 23 Jul 2007
Biovail Responds to Investor Enquiries
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jul 2007
Biovail Provides Update on BVF-033
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 30 May 2007
UK Body Recommends Pfizer's Champix (varenicline) for Smokers
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2007
IMPAX Settles Patent Litigation Related to Generic Wellbutrin(R) XL
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Mar 2007
Teva Announces Agreement with Biovail and Anchen Regarding Generic Wellbutrin XL
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Feb 2007
Watson and GlaxoSmithKline Settle Lawsuit Over Wellbutrin Xl(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 Jan 2007
Wellbutrin XR(R) Receives First European Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2006
IMPAX Announces FDA Approval of Generic Wellbutrin XL 300 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 15 Dec 2006
Anchen Announces Approval of Generic Version of Wellbutrin XL(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2006
OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Excalia(TM) Combination-Therapy to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
Pfizer's Anti-Smoking Pill Champix(R) Approved in Europe
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 37

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 37 additional stories matching:
bupropion
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.